Cited by 189Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismExercise and Physiological Responses

The DOI matches its Crossref record; 115 of the 120 references it cites were found in a registry or an index; none of the 222 sources its claims cite is checked for support yet.

Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions

Open access
de Oliveira dos Santos, Ana Rita, de Oliveira Zanuso, Bárbara, Miola, Vitor Fernando Bordin, Barbalho, Sandra Maria, Santos Bueno, Patrícia C., Flato, Uri Adrian Prync, Detregiachi, Claudia Rucco P., Buchaim, Daniela Vieira, Buchaim, Rogério Leone, Tofano, Ricardo José, Mendes, Claudemir Gregório, Tofano, Viviane Alessandra Capelluppi, dos Santos Haber, Jesselina F.·2021·International Journal of Molecular Sciences

Abstract

Adipose, skeletal, and hepatic muscle tissues are the main endocrine organs that produce adipokines, myokines, and hepatokines. These biomarkers can be harmful or beneficial to an organism and still perform crosstalk, acting through the endocrine, paracrine, and autocrine pathways. This study aims to review the crosstalk between adipokines, myokines, and hepatokines. Far beyond understanding the actions of each biomarker alone, it is important to underline that these cytokines act together in the body, resulting in a complex network of actions in different tissues, which may have beneficial or non-beneficial effects on the genesis of various physiological disorders and their respective outcomes, such as type 2 diabetes mellitus (DM2), obesity, metabolic syndrome, and cardiovascular diseases (CVD). Overweight individuals secrete more pro-inflammatory adipokines than those of a healthy weight, leading to an impaired immune response and greater susceptibility to inflammatory and infectious diseases. Myostatin is elevated in pro-inflammatory environments, sharing space with pro-inflammatory organokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), resistin, and chemerin. Fibroblast growth factor FGF21 acts as a beta-oxidation regulator and decreases lipogenesis in the liver. The crosstalk mentioned above can interfere with homeostatic disorders and can play a role as a potential therapeutic target that can assist in the methods of diagnosing metabolic syndrome and CVD.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This narrative review describes how adipokines, myokines, and hepatokines act through endocrine, paracrine, and autocrine crosstalk to influence insulin resistance, obesity, metabolic syndrome, and cardiovascular disease. It argues these organokines may serve as diagnostic/prognostic biomarkers and therapeutic targets, while calling for more in vivo and mechanistic studies.

Key findings

  • Adipose, skeletal muscle, and liver are the main endocrine organs producing adipokines, myokines, and hepatokines; these biomarkers can be harmful or beneficial and act together in a complex network affecting DM2, obesity, metabolic syndrome, and CVD.
  • Overweight individuals secrete more pro-inflammatory adipokines, leading to impaired immune response and greater susceptibility to inflammatory and infectious diseases; myostatin is elevated in pro-inflammatory environments alongside TNF-α, IL-1, resistin, and chemerin.
  • FGF21 acts as a beta-oxidation regulator and decreases lipogenesis in the liver; exercise shifts secretion toward anti-inflammatory organokines such as irisin, IL-6, IL-15, myonectin, adiponectin, and FGF21, which mitigate harmful effects of myostatin, TNF-α, resistin, chemerin, and fetuin-A.
  • The introduction cites an estimated 1.7 billion people vulnerable to health risks determined by body weight, 2.5 million deaths annually related to increased BMI expected to double by 2030, and CVDs responsible for approximately 17.9 million deaths per year, corresponding to 31% of total deaths worldwide.

Methods

  • Descriptive review using PUBMED-Medline, Embase, and Cochrane databases.
  • Mesh terms were adipokines, myokines, hepatokines, abdominal fat, insulin resistance, obesity, type 2 diabetes, metabolic syndrome, and cardiovascular diseases.
  • Inclusion/exclusion was based on studies that included crosstalk among organokines, not just individual assessment of each one on insulin resistance, diabetes, obesity, metabolic syndrome, and cardiovascular complications.

Limitations

  • The paper states that in vivo experimental studies are further needed addressing crosstalk between adipokines, myokines, and hepatokines to support future clinical treatments, and that biochemical mechanisms of action of organokines are needed to guide future clinical trials.
  • Evident from the text: this is a descriptive/narrative review without a systematic protocol, risk-of-bias assessment, or quantitative synthesis; the search strategy and study selection are reported only briefly.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms22052639

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 222 cited sources checked · 0 supported · 0 flagged

Show all 121 claims

  • It may state two separate claims as one. 121
  • Probably not a substantial claim. 22
131 of 131
  • The paper relies on this without support.

    Adipose, skeletal muscle, and hepatic tissues are the main endocrine organs that produce adipokines, myokines, and hepatokines.

    “Adipose, skeletal, and hepatic muscle tissues are the main endocrine organs that produce adipokines, myokines, and hepatokines.”
  • The paper relies on this without support.

    These biomarkers can be harmful or beneficial and perform crosstalk through endocrine, paracrine, and autocrine pathways.

    “These biomarkers can be harmful or beneficial to an organism and still perform crosstalk, acting through the endocrine, paracrine, and autocrine pathways.”
  • The paper relies on this without support.

    Many organokines are secreted by all three tissues.

    “Moreover, many organokines are secreted by all three tissues.”
  • The paper relies on this without support.

    No review has shown a comprehensive overview of crosstalk among these organokines with focus on insulin resistance, diabetes, metabolic syndrome, and cardiovascular disease.

    “To the best of our knowledge, no review has shown a comprehensive overview of crosstalk or these organokines with focus on insulin resistance, diabetes, metabolic syndrome, and CVD.”
  • The paper relies on this without support.

    Overweight individuals secrete more pro-inflammatory adipokines than healthy-weight individuals, leading to impaired immune response and greater susceptibility to inflammatory and infectious diseases.

    “Overweight individuals secrete more pro-inflammatory adipokines than those of a healthy weight, leading to an impaired immune response and greater susceptibility to inflammatory and infectious diseases.”
  • The paper relies on this without support.

    Myostatin is elevated in pro-inflammatory environments and co-occurs with pro-inflammatory organokines such as TNF-alpha, IL-1, resistin, and chemerin.

    “Myostatin is elevated in pro-inflammatory environments, sharing space with pro-inflammatory organokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), resistin, and chemerin.”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • FGF21 is said to both increase and decrease adipose-tissue lipolysis

    Minor

    The adipokine section attributes lipolysis to FGF21 in white adipose tissue, while the hepatokine section says FGF21 decreases lipolysis in adipose tissue. The text does not explain the opposing effects.

  • Pro-inflammatory organokines are listed as anti-inflammatory

    Minor

    The exercise section lists TNF-α, resistin, chemerin, and fetuin-A among anti-inflammatory organokines. Elsewhere, the paper describes these same substances as contributing to an inflammatory and oxidative-stress scenario.

2 of 2

Citations

Cites

Flagged first, then by citations

Show all 120 references

5 of the 120 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Sandhu, 2020, Cure of obesity in homeopathy: An approach to control a global epidemic, Tantian Univ. J. Homoeopath. Med. Sci., 1, 17
  2. Oliveira, 2019, Atualização da diretriz de prevenção cardiovascular da sociedade brasileira de cardiologia, Arq. Bras. Cardiol., 113, 787

Cited by

Sorted by citations

Items 101–185 of 185

Metadata

Authors
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., Mendes, C. G., Tofano, V. A. C., & dos Santos Haber, J. F.
Affiliations
  • Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho 1001, Marília 17525-902, São Paulo, Brazil
  • Universidade de Marília (BR)
  • Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marilia (UNIMAR), Avenida Hygino Muzzy Filho 1001, Marília 17525-902, São Paulo, Brazil
  • Universidade de São Paulo (BR)
Corresponding author
Barbalho, Sandra Maria
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-03-05
Volume
22
Issue
5
Pages
2639
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3133763745
Cited by
189
References
120
Citations by year
2026: 27 · 2025: 33 · 2024: 39 · 2023: 44 · 2022: 37 · 2021: 9
FWCI
4.94
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Physiology (medical) › Exercise and Physiological Responses
Keywords
adipokines, myokines, hepatokines, crosstalk, hormone signaling, paracrine signaling, autocrine signaling, type 2 diabetes, obesity, metabolic syndrome, cardiovascular disease, myostatin, FGF21, inflammatory cytokines, resistin, chemerin, TNF-α, interleukin-1, fatty acid beta-oxidation, lipogenesis, therapeutic target
MeSH terms
Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Obesity, Cytokines, Metabolic Syndrome, Adipokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review